Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

Stock Information for Incannex Healthcare Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Incannex Healthcare Inc.

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026
Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.